Results for tag: "Idelalisib"

Idelalisib is a type of leukemia drug used to treat chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). It is a kinase inhibitor, meaning it works by blocking certain enzymes that help cancer cells grow and divide. Idelalisib is usually used in combination with other drugs, such as rituximab, to treat CLL and SLL. It is also used to treat follicular lymphoma, a type of non-Hodgkin lymphoma. Idelalisib is taken orally, usually once a day. Idelalisib is a relatively new drug, having been approved by the US Food and Drug Administration (FDA) in 2014. It is the first drug of its kind to be approved for the treatment of CLL and SLL. It has been shown to be effective in treating these types of leukemia, with some patients achieving complete remission. The Idelalisib market is highly competitive, with several companies offering the drug. These include Gilead Sciences, Inc., AbbVie, Inc., and Celgene Corporation. Each company has its own unique formulation of the drug, which may offer different benefits to patients. Show Less Read more